Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Nimotuzumab +1 More for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Buffalo, New York
This trial is testing nimotuzumab and nivolumab, two drugs that help the immune system fight cancer. It targets patients with advanced non-small cell lung cancer that has spread and is hard to treat. These drugs work by helping the immune system recognize and attack cancer cells. Nivolumab is an immune checkpoint inhibitor that has shown promise in treating various cancers, including non-small cell lung cancer (NSCLC).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service